Shares of Caladrius Biosciences Inc (NASDAQ:CLBS) passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.58 and traded as high as $2.67. Caladrius Biosciences shares last traded at $2.67, with a volume of 20,251 shares changing hands.
Separately, Zacks Investment Research lowered Caladrius Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 14th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Caladrius Biosciences has an average rating of “Buy” and an average price target of $8.63.
The company’s fifty day moving average price is $2.42 and its 200-day moving average price is $2.58. The stock has a market capitalization of $27.46 million, a PE ratio of -1.53 and a beta of 1.63.
A hedge fund recently raised its stake in Caladrius Biosciences stock. Vanguard Group Inc. lifted its stake in shares of Caladrius Biosciences Inc (NASDAQ:CLBS) by 7.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 207,973 shares of the biotechnology company’s stock after buying an additional 14,740 shares during the quarter. Vanguard Group Inc. owned about 2.00% of Caladrius Biosciences worth $474,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.09% of the company’s stock.
Caladrius Biosciences Company Profile (NASDAQ:CLBS)
Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Featured Story: Dividend Achievers
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.